Pacira BioSciences (NASDAQ:PCRX) Posts Earnings Results, Beats Estimates By $0.08 EPS

Pacira BioSciences (NASDAQ:PCRX) posted its earnings results on Tuesday. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.08, FiscalAI reports. The firm had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a return on equity of 9.61% and a net margin of 1.96%.Pacira BioSciences’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 EPS.

Here are the key takeaways from Pacira BioSciences’ conference call:

• Second-quarter revenue increased 6% to $192.4 million, led by EXPAREL sales growth of 3% to $147.8 million, ZILRETTA growth of 4%, and iovera° growth of 21%.
• EXPAREL continued gaining share despite softness in deferrable elective soft-tissue procedures. Expanded commercial-payer coverage, including UnitedHealthcare, brings separate reimbursement to more than 150 million covered lives, supporting further adoption in outpatient settings.
• Pacira lowered its 2026 total revenue guidance to $735 million-$760 million from $745 million-$770 million, primarily reflecting the iovera° divestiture; consolidated non-GAAP gross margin also declined to 78% from 82% a year ago.
• The company expects several pipeline catalysts by year-end, including data from ZILRETTA’s shoulder osteoarthritis study, iovera°’s spasticity study, and Part A of the PCRX-201 Phase II trial. Pacira also reported $251 million in cash and investments before receiving the $70 million upfront payment from Zimmer Biomet.
• Pacira completed the iovera° divestiture to Zimmer Biomet for up to $140 million, filed EXPAREL for approval in South Korea through LG Chem with potential revenue beginning in 2027, and said it remains open to additional partnerships while focusing capital on near-term, risk-managed growth opportunities.

Pacira BioSciences Trading Up 2.3%

Shares of PCRX stock traded up $0.57 during trading hours on Thursday, hitting $25.44. 240,368 shares of the company were exchanged, compared to its average volume of 693,732. The firm has a fifty day moving average of $24.61 and a 200 day moving average of $23.35. The company has a quick ratio of 3.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.56. Pacira BioSciences has a 1 year low of $18.80 and a 1 year high of $27.66. The firm has a market cap of $1.00 billion, a PE ratio of 72.47 and a beta of 0.27.

More Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Pacira announced publication of positive two-year Phase 1 data for PCRX-201 in Annals of the Rheumatic Diseases. The update provides additional clinical support for the company’s pipeline and may improve investor confidence in the long-term growth potential of the program. Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
• Positive Sentiment: Second-quarter earnings exceeded expectations: adjusted EPS was $0.73 versus the $0.65 consensus estimate, while revenue of $192.4 million topped forecasts of $191.06 million and increased 6.2% year over year. The results indicate continued commercial execution and supported the stock’s move to a one-year high. Pacira BioSciences Second-Quarter 2026 Earnings
• Positive Sentiment: Needham raised its price target on PCRX to $33 from $32 and maintained a “buy” rating, implying substantial potential upside from recent trading levels. Needham Raises Pacira BioSciences Price Target
• Neutral Sentiment: Pacira is targeting 160 million covered lives for EXPAREL, its key commercial product, as part of its growth strategy. Management reiterated 2026 revenue guidance of $735 million to $760 million. Pacira Outlines 2026 Revenue Guidance
• Neutral Sentiment: RBC raised its price target to $25 from $24 but retained a “sector perform” rating, signaling limited upside at recent prices and a more cautious view than Needham’s. RBC Raises Pacira BioSciences Price Target
• Negative Sentiment: The 2026 revenue outlook of $735 million to $760 million is below the analyst consensus of approximately $767.8 million. The guidance reduction offsets some of the quarter’s strength and raises concerns about near-term growth momentum. Pacira Q2 Earnings and 2026 Outlook

Wall Street Analyst Weigh In

Several equities analysts recently commented on PCRX shares. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Pacira BioSciences in a report on Wednesday, July 1st. Royal Bank Of Canada raised their price objective on shares of Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Needham & Company LLC raised their price target on Pacira BioSciences from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Weiss Ratings upgraded Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pacira BioSciences has a consensus rating of “Hold” and an average price target of $29.80.

Insider Buying and Selling

In related news, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the transaction, the senior vice president owned 62,284 shares of the company’s stock, valued at approximately $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Vident Advisory LLC grew its holdings in shares of Pacira BioSciences by 15.0% during the 4th quarter. Vident Advisory LLC now owns 23,571 shares of the company’s stock worth $610,000 after purchasing an additional 3,075 shares during the period. Empowered Funds LLC boosted its position in Pacira BioSciences by 1.9% during the 4th quarter. Empowered Funds LLC now owns 227,605 shares of the company’s stock worth $5,890,000 after purchasing an additional 4,167 shares during the period. XTX Topco Ltd acquired a new stake in Pacira BioSciences in the 4th quarter valued at $2,146,000. Millennium Management LLC raised its position in Pacira BioSciences by 73.3% in the fourth quarter. Millennium Management LLC now owns 122,606 shares of the company’s stock valued at $3,173,000 after purchasing an additional 51,848 shares during the period. Finally, Inspire Investing LLC boosted its position in shares of Pacira BioSciences by 3.2% in the fourth quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock worth $465,000 after buying an additional 556 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.